MedTrace Logo

Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19

NCT04746066 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2022-05-05

No results posted yet for this study

Summary

The COVID-19 pandemic is causing many deaths around the world, putting a strain on health services. Patients with pre-existing chronic conditions are most affected by the SARS-COV2 infection. Infectious complications are a common cause of mortality and one of the main causes of morbidity in all these diseases. The main objective of this project is the assessment of patients with thalassemia, drepanocytosis, other haemoglobinopathies and rares inherited anemias suffering from SARS-COV-2 to:

1. Obtain clinical and epidemiological data that can provide information on a possible increased vulnerability of these patients to SARS-COV-2 infection;
2. Sharing therapeutic approaches considering the lack of information about the treatment.

Conditions

  • Haemoglobinopathies

Sponsors & Collaborators

  • Società Italiana Talassemie ed Emoglobinopatie

    lead OTHER

Principal Investigators

  • Gian Luca Forni · Ospedali Galliera - SSD Microcitemia, anemie congenite e dismetabolismo del ferro

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746066 on ClinicalTrials.gov